IL2 and Erythema: Topical corticosteroids primarily target fibroblasts and keratinocytes located between the dermis and epidermis and bind to specific regions that regulate the inflammatory process, inhibiting the release of IL-1, IL-2, IL-6, interferon, tumor necrosis factor, and T-cell proliferation, resulting in anti-inflammatory, antiproliferative effects and reduced erythema [140].